Seattle Genetics licenses technology to GSK

12/21/2009 | Reuters

Seattle Genetics granted GlaxoSmithKline rights to use its antibody-drug conjugate technology. GSK will pay Seattle Genetics $12 million upfront and as much as $390 million in milestone fees if all ADC products created as a result of the deal reach the market.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY